Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

Elizabeth Seiverling, Emmy M. Fernanadez, David Adams

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

Original languageEnglish (US)
Pages (from-to)368-369
Number of pages2
JournalJournal of drugs in dermatology : JDD
Volume5
Issue number4
StatePublished - Jan 1 2006

Fingerprint

Epidermal Growth Factor Receptor
Skin
Sulfacetamide
Triamcinolone
Clindamycin
Non-Small Cell Lung Carcinoma
Colorectal Neoplasms
gefitinib

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Seiverling, Elizabeth ; Fernanadez, Emmy M. ; Adams, David. / Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. In: Journal of drugs in dermatology : JDD. 2006 ; Vol. 5, No. 4. pp. 368-369.
@article{452422a992f941659d575db3d0b7a05c,
title = "Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.",
abstract = "EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1{\%} cream twice daily, clindamycin 1{\%} lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.",
author = "Elizabeth Seiverling and Fernanadez, {Emmy M.} and David Adams",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
volume = "5",
pages = "368--369",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "4",

}

Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption. / Seiverling, Elizabeth; Fernanadez, Emmy M.; Adams, David.

In: Journal of drugs in dermatology : JDD, Vol. 5, No. 4, 01.01.2006, p. 368-369.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.

AU - Seiverling, Elizabeth

AU - Fernanadez, Emmy M.

AU - Adams, David

PY - 2006/1/1

Y1 - 2006/1/1

N2 - EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

AB - EGFR Inhibitors are used to treat Non-Small-Cell Lung Cancer (NSCLC) and colorectal cancer (CRC). A common side effect of EGFR Inhibitors is a follicular/pustular skin eruption. We report a case of gefitinib (Iressa) associated skin eruption. The treatment regimen consisted of triamcinolone 0.1% cream twice daily, clindamycin 1% lotion twice daily and sodium sulfacetamide lotion twice daily. The clinical presentation, etiology, and management options of EGFR Inhibitor associated skin eruptions are discussed.

UR - http://www.scopus.com/inward/record.url?scp=33748913430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748913430&partnerID=8YFLogxK

M3 - Article

C2 - 16673807

AN - SCOPUS:33748913430

VL - 5

SP - 368

EP - 369

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 4

ER -